Loading stock data…
CytomX Therapeutics, Inc. (CTMX)
$3.74+0.34 (+10.00%)
Market ClosedLast close Jun 29
CytomX Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CytomX Therapeutics, Inc. in the Healthcare sector is trading at $3.74 with a market capitalization of $701M. Wall Street consensus targets $12.50 (8 analysts), implying a +234.2% move over the next 12 months. The stock is currently 54% below its 52-week high of $8.21, remaining 8.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. Risk note: RSI 81 is overbought against a weak tape. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +234.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 81 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.26M↑ | $663,000↓ | $5.96M↓ | $18.66M↓ | $50.92M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.67M↑ | -$27.93M↓ | -$15.77M↓ | -$1.29M↓ | $22.62M |
| Net Income | -$18.25M↑ | -$26.51M↓ | -$14.23M↓ | -$154,000↓ | $23.52M |
Peer Comparison
JNJUNHPFE
Fundamentals
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology bio...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$701.00M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-18.48%
Volume
Today's trading volume
6.84M
Recent News
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?
CytomX Therapeutics Inc. (NASDAQ:CTMX) is one of the best growth stocks under $30 to buy now. On June 3, CytomX expanded its research collaboration with Regeneron to develop next-gen conditionally-activated bispecific cancer therapies. By combining CytomX’s PROBODY masking platform with Regeneron’s Veloci-Bi technology, the partnership aims to create treatments that remain inactive until reaching the […]
How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments
The latest analyst update on CytomX Therapeutics keeps the existing price targets unchanged, signaling no shift in published expectations for the stock right now. As the story around CytomX develops, you will see how to track these price targets over time and incorporate them into your own view of the company. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value CytomX Therapeutics. Do your thoughts align with the Bull or Bear...
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
Regeneron Pharmaceuticals (REGN) has been back in focus after expanding its cancer therapy partnership with CytomX Therapeutics, a deal with up to $4b in potential milestones, alongside highly favorable Lynozyfic trial results in light chain amyloidosis. See our latest analysis for Regeneron Pharmaceuticals. Despite the Oncology headlines, the stock’s recent momentum has cooled, with the 30 day share price return down 10.47% and the 90 day share price return down 17.26%, even as the 1 year...
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.
Why Regeneron (REGN) Stock Is Trading Up Today
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 2.9% in the afternoon session after the company announced an expanded cancer therapy collaboration and reported positive clinical trial data for one of its treatments.